Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The NeuroRegen Scaffold is a linear-ordered collagen scaffold (LOCS) developed by the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences for the treatment of spinal cord injury (SCI). It is designed to be surgically implanted into the site of a spinal cord lesion to provide a physical bridge and guidance for axonal regeneration. The scaffold's ordered fibers mimic the natural architecture of the spinal cord, facilitating the growth of neurites across the injury gap. It can be used as a standalone biomaterial or as a delivery vehicle for bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) to further promote neural repair and modulate the inhibitory environment of the lesion. Clinical studies in patients with complete acute and chronic SCI have demonstrated its safety and potential for improving sensory and motor functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NeuroRegen Scaffold.